HIF1 is a transcription factor activated under hypoxic condition in many cancer types and has been implicated in cancer cell proliferation, invasion and energy metabolism. Towards understanding the role of HIF1 mediated transcription in gastric cancer, the HIF1 gene signatures established to date were analyzed for their expression across the mRNA profiles of gastric tumors. HIF1 regulated genes were identified to involve and associated with the signaling pathways and processes such as integrin signaling, Wnt, P53, EGF, FGF, VEGFA, PI3K, TGFβ and NFkB signaling pathways. The HIF1a genes were identified to play a significant role in energy metabolism including glycolysis, drug resistance due to epithelial to mesenchymal transition and cancer cell survival. In gastric tumors, the HIF1 regulated genes were observed to express in diffuse, poorly differentiated and stage-3 tumors. The analyses reveal i) activation of HIF1 in a sub-set of gastric tumors, ii) the pathways associated with the HIF1 activation in gastric tumors, and iii) genes involved in HIF1 mediated transcription in gastric cancer. We are further investigating the drugs that would best suit for this sub-set of tumors with activated HIF1. 
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